Market Strategy
A supplement does not have a fixed regulatory identity. It has one per jurisdiction.
In Canada it is a natural health product requiring a pre-market licence. In the United States it is a dietary supplement requiring no approval at all. In Australia it is a complementary medicine regulated under therapeutic goods legislation. In the European Union it is a food supplement governed by food law, with the details left substantially to individual member states.
Those are not variations on a theme. They are four different bodies of law with different ingredient rules, different claim frameworks and different manufacturing expectations. A roadmap that treats international expansion as one project will fail at the first divergence.
When assessing a market, four questions determine most of the cost and timeline.
Is there pre-market review? Canada and Australia’s assessed pathway say yes. The US and Australia’s listed pathway say no. This determines whether your mistakes surface before or after you have spent money.
Is the ingredient list open or closed? Australia and the EU’s vitamin and mineral rules work from permitted lists, where anything absent is prohibited. The US works from the opposite premise. Canada sits in between, with monographs defining the easy path and a harder pathway for everything else.
Are claims pre-approved or self-substantiated? The EU and Canada require approved claims in prescribed wording. The US allows self-substantiated structure function claims. Australia restricts listed medicines to a published indications list, used verbatim.
Is manufacturing licensed or inspected? Australia requires GMP licensing or clearance before a product can be listed, which regularly disqualifies an existing contract manufacturer. Canada licenses the site. The US registers and inspects.
The general principle is to enter your most restrictive market first, where commercially viable.
A formula built to Australian permitted ingredient limits, with Canadian monograph doses and EU-compliant claims, will usually clear the US without modification. The reverse is rarely true. Building to US norms and expanding outward means discovering at each new border that the ingredient is not permitted, the dose is out of range, or the claim has no local equivalent.
There is a commercial counterargument, which is that the US is the largest market and waiting for a Canadian or Australian file delays revenue. That is legitimate. The point is to make the trade knowingly, with the reformulation cost priced in, rather than discovering it eighteen months later.
The work assembled for one market is not evenly portable, and knowing which parts travel changes how you build the first file.
Manufacturing qualifications transfer well. A site holding TGA GMP clearance or a Canadian site licence carries weight with regulators, distributors and retail buyers elsewhere. This is the single most transferable asset a regulatory file produces.
Specifications, stability data and analytical methods transfer well. The finished product specification built for a Canadian application is most of what a certification body or a European distributor will ask for.
Claim substantiation transfers partially. The evidence transfers, the permitted wording does not. A claim approved in Canada has no standing in the EU, but the dossier behind it substantially shortens an Article 13.5 application.
Label artwork transfers poorly. Bilingual requirements in Canada, the Product Facts table, EU multilingual obligations and Australian mandatory statements mean packaging is usually market specific. Plan for regional artwork from the start rather than treating it as an adaptation.
The expensive version of international expansion is the one where the roadmap is built after the packaging is printed.
A market assessment costs a fraction of a packaging run. It tells you which markets the product can enter as designed, which need a formula change, which need a claim change, and which are not worth the effort at your volume. That is the document that should exist before the first artwork brief, not after the first import refusal.